Focus on Cancer Collaboration
The World Cancer Day - Thursday February 4th, 2021
The seventh meeting Focus on Cancer Collaboration is arranged by Medicon Village in collaboration with Lund University Cancer Centre (LUCC), Create health and LU Innovation.
We invite you to interact around research and innovation in the oncology area. How can new ideas be created by working cross borders? How can industry, academia and healthcare sector work together?
PROGRAM (digital meeting)
A PDF version of the program is available under "Bilagor"/"Attachments".
09.00-09.10 Welcome; Medicon Village & project team
09.10-10.10 Keynote session
Thinking out of the box of ineffectual standard-of-care: hallmark co-targeting with repurposed drugs in glioblastoma
Professor Douglas Hanahan
10.10-10.25 BREAK (15 min breakout sessions)
10.25-10.55 Short presentations:
- Research & innovation collaborations in the establishment of the first clinic at Medicon Village
Åsa Dahm & Göran Ahlgren - Improved cancer diagnostics and monitoring using circulating DNA
Lao Saal
11.00-11.30 Inspirational lecture:
How to perform and thrive during the new normal! Easy ways to boost you brain, focus and wellbeing
Trine Grönlund
11.30-11.45 BREAK (15 min breakout sessions)
11.45-12.45 EU funding; Un-explored opportunities
- Introduction to collaborative projects in Horizon Europe
Anna-Karin Wihlborg - What are the benefits from participating in collaborative EU projects? Success stories from academia and industry
Anders Bjartell & Björn Walse
12.45-13.30 BREAK (LUNCH)
13.30-13.40 Discussion sessions: Introduction to Challenges and LUCC focus groups, Kristian Pietras & Ceclilia Jädert
To sum up the meeting, there will be four parallel discussion sessions - “Challenges” - where clinicians, academic researchers and company representatives will have a unique opportunity to discuss urgent topics from the perspective of the different participating LUCC reference groups:
The different focus groups will discuss unmet clinical needs in the first session and preclinical or technological need in the second
13.40-14.25 Challenge part I - Unmet clinical needs – Track 1-4
1. Omics, bioinformatics and diagnostics
2. Gastrointestinal cancer
3. Clinical trials & drug development
4. Urological malignancies
14.25-14.35 BREAK
14.35-15.20 Challenge part II - Pre-clinical or technological need - Track 1-4
1. Omics, bioinformatics and diagnostics
2. Gastrointestinal cancer
3. Clinical trials & drug development
4. Urological malignancies
END OF MEETING
ORGANIZERS
Lund University Cancer Centre (LUCC) | LU Innovation | Medicon Village | Create health
SPEAKERS:
- Professor Douglas Hanahan, Director of The Swiss institute of experimental cancer research, Lausanne Switzerland
- Åsa Dahm CEO, Peritus clinic
- Göran Ahlgren MD, PhD, Senior lead consultant at Peritus clinic
- Lao Saal, MD PhD founder CEO SAGA Diagnostics
- Trine Grönlund, Innergi Labbet AB
- Anna-Karin Wihlborg, Research Services, Lund University
- Professor Anders Bjartell,Urological cancer, Malmö
- Dr. Björn Walse, Saromics Biostructures AB.
CHALLENGES: four parallel discussion sessions based on LUCC focus groups
In the “Challenges” clinicians, academic researchers and company representatives will have a unique opportunity to discuss urgent topics from the perspective of each participating LUCC reference group.
Take the opportunity to engage in scientific discussions of your interest by signing up to one of the topics at each Challenge session (Part I and II). The moderators (coordinators of LUCC reference group) will start the discussion with a short background and the objective is to initiate new ideas and future collaborations.
Part I - Unmet clinical needs
1. Omics, bioinformatics and diagnostics – Moderators: Kajsa Paulsson, Emma Niméus
How to incorporate new biomarkers into the clinics to tailor treatment to individual patients? (Translate evidence generated from large data bases and advanced bioinformatic analysis into clinical decision
2. Gastrointestinal cancer – Moderators: Pamela Buchwald, Roland Andersson
How to improve diagnostic staging and prediction of complete response in rectal cancer?
3. Clinical trials & drug development – Moderators: Marcus Järås, Ana Carnerio
How to identify patients in need for patient-centered drug development and define appropriate endpoints?
4. Urological malignancies – Moderators: Håkan Axelsson, Gottfrid Sjödahl
How to identify decision points for aggressive therapy options versus standard of care?
Part II - Pre-clinical or technological need
1. Omics, bioinformatics and diagnostics – Moderators: Kajsa Paulsson, Emma Niméus
How to distinguish between driver and passenger mutations in individual tumors? Which ones are driving tumor progression and could potentially be evaluated for targeted treatments?
2. Gastrointestinal cancer – Moderators: Pamela Buchwald, Roland Andersson
Modeling pancreatic cancer: how can we improve translational models for the evaluation of new cancer therapies?
3. Clinical trials & drug development – Moderators: Marcus Järås, Ana Carnerio
How to translate pre-clinical findings into clinical trials? How do we increase biology-driven drug development to manage the complexity of cancer.
4. Urological malignancies – Moderators: Håkan Axelsson, Gottfrid Sjödahl
Modeling urological cancer: How to explore and combine different pre-clinical models to test hypothesis generated from clinical data?
